Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy. [electronic resource]
Producer: 20161213Description: 889-97 p. digitalISSN:- 1399-3003
- Adult
- Aged
- Aged, 80 and over
- Dose-Response Relationship, Drug
- Double-Blind Method
- Exercise Test
- Female
- Homeodomain Proteins -- adverse effects
- Humans
- Idiopathic Pulmonary Fibrosis -- drug therapy
- Lung -- physiopathology
- Male
- Middle Aged
- Netherlands
- Recombinant Proteins -- adverse effects
- Respiratory Function Tests
- Serum Amyloid P-Component -- adverse effects
- Treatment Outcome
- United States
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.